Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: chaz who wrote (1231)	3/7/1998 8:22:00 PM
From: David S.	Read Replies (1) \| Respond to of 5736

Apologies are not required to people who fabricate things in order to tout their pipe dreams. I am waiting for a sentient being to post fundamental reasons to be optimistic about the future of chromatic color pseudoscience. to date, the fundamental questions that I and roughly 2 other people have posed on this thread have not been answered. Instead, the questions themselves and I have been attacked for not agreeing to the "party line". The attitude was similar in Nazi Germany. If you hadn't noticed, that regime was destroyed. The following is from the 4th quarter, 1997 press release by SpectRX. Please note their evaluation of the bilirubin market. Please address the issue. Then, have a glass of ovaltine. SpectRx, Inc. is a medical technology development company that specializes in less and non-invasive alternatives to existing blood tests and medical diagnostic and monitoring procedures. The SpectRx technologies are designed to reduce or eliminate pain, are convenient to use and provide rapid results at the point of care. Programs currently under development by SpectRx are: A painless and bloodless glucose meter with Abbott Laboratories which targets the estimated $2 billion annual diabetes finger stick blood glucose market; a non-invasive diabetes screening product with Boehringer-Mannheim Corporation designed to help identify the approximately 50 million undiagnosed diabetics worldwide; and, a non-invasive infant jaundice (BiliCheckTM) screening and monitoring product with Healthdyne Technologies which addresses an estimated $180 million worldwide market. note: by posting this via cut and paste from their web site, I am NOT recommending investing in SPRX - it merely illustrates the hype surrounding chromatic color pseudoscience.